Changzhou's Generic Ticagrelor Receives Approval in the U.S.
Annora's Generic Ticagrelor Receives Approval in the U.S.
A pipeline pivot from type 2 diabetes to cardiovascular disease appears to be paying off for PhaseBio Pharmaceuticals. Weeks after unveiling positive Phase IIb data, the company announced positive interim Phase III data demonstrating lead product candidate bentracimab’s ability to reverse the antiplatelet effects of AstraZeneca’s blood-thinner Brilinta.
PhaseBio’s Brilinta reversal drug has scored a midstage win without any adverse events or blood clot issues.
The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that have yet to be certified by peer review.
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it has entered into an exclusive licensing agreement with Alfasigma S.p.A., a privately owned specialty pharmaceutical company focused on commercializing medicines in Europe and other key markets, for the commercialization of bentracimab. The agreement covers countries in the European Union and European Economic Area, as well as the United Kingdom, Russia, Ukraine and other countries within the Commonwealth of Independent States. Bentracimab is a novel, human monoclonal antibody fragment that in earlier clinical trials has shown immediate and sustained reversal of the antiplatelet effects of Brilinta®/Brilique® (ticagrelor).
PhaseBio Pharmaceuticals is signing a manufacturing partner for its Brilinta reversal agent as it ushers the drug through phase 3 and, it hopes, an FDA submission and approval. The company is teaming up with CDMO BioVectra to produce the treatment, bentracimab, at commercial scale.
NEW YORK -- November 17, 2020 -- A higher level of platelet inhibition achieved with ticagrelor versus clopidogrel does not translate into lower rates of periprocedural myocardial infarction or myocardial injury within 48 hours of high-risk percutaneous coronary intervention (PCI) among patients with stable coronary disease, according to a study presented at the Virtual 2020 American Heart Association (AHA) Scientific Sessions.
A new study found the rate of heart attack and severe complications before, during or soon after elective surgery to open a blocked artery was similar between patients treated with clopidogrel and those who received the more potent antiplatelet medication ticagrelor.